Antithrombotic Management After Left Atrial Appendage Closure: Current Evidence and Future Perspectives

Circ Cardiovasc Interv. 2023 May;16(5):e012812. doi: 10.1161/CIRCINTERVENTIONS.122.012812. Epub 2023 May 16.

Abstract

Left atrial appendage closure is an alternative to chronic oral anticoagulation to prevent embolic events related to nonvalvular atrial fibrillation. After device implantation, antithrombotic treatment is prescribed to prevent device-related thrombosis, a dreadful complication associated with an increased risk of ischemic events. However, the optimal antithrombotic treatment after left atrial appendage closure, effective on both device-related thrombus prevention and bleeding risk mitigation, remains to be determined. In more than 10 years experience with left atrial appendage closure, a wide range of antithrombotic treatments have been used, mostly in observational studies. In this review, we analyzed the body of evidence for each antithrombotic regimen after left atrial appendage closure to provide tools to guide the physician choice and describe future perspectives in the field.

Keywords: anticoagulants; atrial appendage; atrial fibrillation; stroke, thrombosis; thromboembolism.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anticoagulants / adverse effects
  • Atrial Appendage*
  • Atrial Fibrillation* / complications
  • Atrial Fibrillation* / diagnosis
  • Atrial Fibrillation* / drug therapy
  • Fibrinolytic Agents / adverse effects
  • Humans
  • Stroke* / diagnosis
  • Stroke* / etiology
  • Stroke* / prevention & control
  • Thrombosis* / etiology
  • Thrombosis* / prevention & control
  • Treatment Outcome

Substances

  • Anticoagulants
  • Fibrinolytic Agents